Abstract
The COVID-19 pandemic exposed, with few exceptions, a global deficiency in delivering systematic, data-driven guidance to protect citizens and coordinate vaccination programs. At the same time, medical histories are routinely recorded in most healthcare systems and are instantly available for risk assessment. Here, we demonstrate the utility of medical history in determining the risk for 1,883 diseases across clinical specialties and facilitating the rapid response to emerging health threats at the example of COVID-19. We developed a neural network to learn disease-specific risk states from routinely collected health records of 502,460 UK Biobank participants, demonstrating risk stratification for nearly all conditions, and validated this model on 229,830 individuals from the All of US cohort. When integrated into Cox Proportional Hazard Models, we observed significant discriminative improvements over basic demographic predictors for 1,774 (94.3%). After transferring the unmodified risk models to the All of US cohort, the discriminate improvements were replicated for 1,347 (89.8%) of 1,500 investigated endpoints, demonstrating model generalizability across healthcare systems and historically underrepresented groups. We then show that these risk states can be used to identify individuals vulnerable to severe COVID-19 and mortality. Our study demonstrates the currently underused potential of medical history to rapidly respond to emerging health threats by systematically estimating risk for thousands of diseases at once at minimal cost.
Competing Interest Statement
U.L. received grants from Bayer, Novartis, Amgen, consulting fees from Bayer, Sanofi, Amgen, Novartis, Daichy Sankyo, and honoraria from Novartis, Sanofi, Bayer, Amgen, Daichy Sankyo. J.D. received consulting fees from GENinCode UK Ltd, honoraria from Amgen, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi, Takeda, Novo Nordisk, Bayer, and is chief medical advisor to Our Future Health. R.E. received honoraria from Sanofi and consulting fees from Boehringer Ingelheim. All other authors do declare no competing interests.
Funding Statement
This project has been funded by the Charite - Universitaetsmedizin Berlin and the Einstein Foundation Berlin, throught the Einstein BIH Visiting Fellowship awarded to J.D. The study has been supported by the BMBF-funded Medical Informatics Initiative (HiGHmed, 01ZZ1802A - 01ZZ1802Z) and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 437531118 SFB 1470.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We would like to acknowledge the support of the UK Biobank and the All of Us Research Program in providing access to their respective datasets. This research has been conducted using data from the UK Biobank (application number 51157) and the All of Us Research Program (by Stefan Hegselmann UserID 5703). Both studies have received ethical approval from their respective institutional review boards and have obtained informed consent from participants. We are grateful to the participants who generously contributed their time and data to make this research possible.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵§ shared senior authorship
This version of the manuscript has been revised following the feedback of the scientific community. We added additional experiments and further improved the risk prediction models.
Data availability
UK Biobank data, including all linked routine health records, are publicly available to bona fide researchers upon application at http://www.ukbiobank.ac.uk/using-the-resource/. In this study, primary care data was used following the COPI regulations. The All Of Us cohort data were provided by the All Of Us Research Program by permission that can be sought by scientists and the public alike. Currently, however, data access requires affiliation with a US institution. All patient data used throughout this study has been subject to patient consent as covered by the UK Biobank and All Of Us. Detailed information on the predictors and endpoints is presented in Supplementary Tables 1-3.
